Aurobindo Pharma receives USFDA Approval for Azithromycin Oral Suspension

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin Oral Suspension 100 mg /5 mL and 200 mg/5 mL. Azithromycin oral suspension, a generic version of Pfizer Inc’s Zithromax® oral suspension. The product will be launched in November 2018. Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of US$ 71 million for the twelve months ending August 2018, according to IQVIA.